Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Early Anemia Response in Patients with Myelofibrosis Treated with Pacritinib in Real-Word Clinical Settings

John O. Mascarenhas, Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, Raajit Rampal

Blood (2024) 144 (Supplement 1): 6650.

https://doi.org/10.1182/blood-2024-210598

Published: 2024

Journal Articles

Transplant Related Outcomes in Patients with Hemophagocytic Lymphohistiocytosis Treated with Emapalumab As a Bridge to Hematopoietic Stem Cell Transplantation: The Real-HLH Study

Carl E Allen, Shanmuganathan Chandrakasan, Michael B. Jordan, Jennifer W Leiding, Michael Marrone, Abiola Oladapo, Priti Pednekar, Kelly J. Walkovich, John Yee

Blood (2024) 144 (Supplement 1): 3489.

https://doi.org/10.1182/blood-2024-204680

Published: 2024

Journal Articles

Real-Word Effectiveness of Pacritinib in Patients with Myelofibrosis Who Have Thrombocytopenia and Anemia

Raajit Rampal, Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 6649.

https://doi.org/10.1182/blood-2024-210274

Published: 2024

Journal Articles

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (INTO-HLH) Patient Registry: Study Design and Clinical Characteristics

Adi Zoref-Lorenz, David C. Fajgenbaum, Shanna Korn, Tayloranne Kaufmann, Brady Anderson, Abiola Oladapo, Laura Saltonstall, Deanna Fournier, Edward Behrens, Carl E Allen, Michael B. Jordan

Blood (2024) 144 (Supplement 1): 5389.

https://doi.org/10.1182/blood-2024-209715

Published: 2024

Journal Articles

Real-World Treatment Patterns and Outcomes in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Interim Analysis Results

Srikanth Nagalla, Moshe Y. Levy, Shruti Chaturvedi, Scott Kolodny, Abiola Oladapo, Chelsea Bernheisel, Elyse Swallow, Debbie Goldschmidt, Ali Greatsinger, Kirthana Sarathy, Loren Ormenaj, Michael Vredenburg

Blood (2024) 144 (Supplement 1): 3700.

https://doi.org/10.1182/blood-2024-200320

Published: 2024

Journal Articles

Hematologic Improvement Experienced By Pacritinib-Treated Patients with Myelofibrosis in Real-World Clinical Settings

Michael Marrone, Lisa Morere, Abiola Oladapo, Purvi Suthar, Teena Sura, Anupama Vasudevan, Michael Vredenburg, Jia Zeng, Raajit Rampal, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 3814.

https://doi.org/10.1182/blood-2024-210826

Published: 2024

Journal Articles

Real-World Treatment Patterns and Outcomes Among Patients with Secondary Hemophagocytic Lymphohistiocytosis Treated with Emapalumab in the United States: The Real-HLH Study

Carl E Allen, Shanmuganathan Chandrakasan, Michael B. Jordan, Jennifer W Leiding, Abiola Oladapo, Priti Pednekar, Kelly Walkovich, John Yee

Blood (2023) 142 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2023-186948

Published: 2023

Journal Articles

Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Study Design

Srikanth Nagalla, Shruti Chaturvedi, Moshe Levy, Scott Kolodny, Abiola Oladapo, Chelsea Bernheisel, Brian Jamieson, Debbie Goldschmidt, Elyse Swallow, Ali Greatsinger, Michael Vredenburg

Blood (2023) 142 (Supplement 1): 5127.

https://doi.org/10.1182/blood-2023-189009

Published: 2023

Journal Articles

Real-World Treatment Patterns and Outcomes Among Patients with Primary Hemophagocytic Lymphohistiocytosis with and without Infection at Diagnosis and Treated with Emapalumab: The Real-HLH Study

Carl E Allen, Shanmuganathan Chandrakasan, Michael B. Jordan, Jennifer W Leiding, Abiola Oladapo, Priti Pednekar, Kelly Walkovich, John Yee

Blood (2023) 142 (Supplement 1): 2534.

https://doi.org/10.1182/blood-2023-181777

Published: 2023

Journal Articles

Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study

Carl E. Allen, Shanmuganathan Chandrakasan, Michael B Jordan, Jennifer W Leiding, Abiola Oladapo, Priti Pednekar, Kelly J. Walkovich, John Yee

Blood (2022) 140 (Supplement 1): 2595–2596.

https://doi.org/10.1182/blood-2022-166649

Published: 2022

Journal Articles

Avatrombopag Treatment Response in Patients with Immune Thrombocytopenia: A Real-World Evidence Study

Abiola Oladapo, Scott Kolodny, Michael Vredenburg, Brian Jamieson, Elyse Swallow, Debbie Goldschmidt, Miriam L. Zichlin, Mikhail Davidson, Louise Yu, John Yee

Blood (2022) 140 (Supplement 1): 10889–10890.

https://doi.org/10.1182/blood-2022-169162

Published: 2022

Journal Articles

Real-World Demographic and Clinical Characteristics of Patients Initiating Avatrombopag in the US: The Real-AVA Study

Scott Kolodny, Abiola Oladapo, Michael Vredenburg, Brian Jamieson, Elyse Swallow, Debbie Goldschmidt, Miriam L. Zichlin, Priscilla Lopez, Mikhail Davidson, John Yee

Blood (2022) 140 (Supplement 1): 13150–13151.

https://doi.org/10.1182/blood-2022-169369

Published: 2022

Journal Articles

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): The into-HLH Registry

Adi Zoref-Lorenz, David C. Fajgenbaum, Sheila K. Pierson, Abiola Oladapo, John Yee, Nitya Gulati, Carl E. Allen, Michael B. Jordan

Blood (2022) 140 (Supplement 1): 11170–11171.

https://doi.org/10.1182/blood-2022-170288

Published: 2022

Journal Articles

Real-World Treatment Patterns and Outcomes in Patients with Hemophagocytic Lymphohistiocytosis (HLH) and Other Clinical Conditions Treated with Emapalumab: The Real-HLH Study Design

Carl E. Allen, Jennifer Leiding, Shanmuganathan Chandrakasan, Kelly J. Walkovich, Abiola Oladapo, John Yee, Priti Pednekar, Sajjad Raza, Michael B Jordan

Blood (2021) 138 (Supplement 1): 4991.

https://doi.org/10.1182/blood-2021-148555

Published: 2021

Journal Articles

Retrospective Chart Review of Gastrointestinal Bleeding in Patients with Von Willebrand Disease

Jonathan C. Roberts, MD, Miguel A. Escobar, MD, Suchitra Acharya Acharya, MD, Nina Hwang, MD, Michael Wang, MD, Sarah A Hale, MS, PhD, Abiola Oladapo, PhD, Sohaib Asghar, Syed Mehdi, MD, Peter A. Kouides, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-133499

Published: 2020

Journal Articles

Prevalence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: A Retrospective US Claims Database Analysis

Abiola Oladapo, PhD, Elyse Swallow, Allison Briggs, Miriam L. Zichlin, Bjorn L Mellgard

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140756

Published: 2020

Journal Articles

Analysis of Bleeding and Treatment Patterns in Children and Adolescents before and after Von Willebrand Disease Diagnosis Using Data from a US Medical Claims Database

Jonathan C. Roberts, Lynn M Malec, MD, Imrran Halari, Sarah Hale, Abiola Oladapo, Robert Sidonio

Blood (2019) 134 (Supplement_1): 2117.

https://doi.org/10.1182/blood-2019-122164

Published: 2019

Journal Articles

Estimation of the Economic Burden Associated with Major Surgery Due to Von Willebrand Disease Based on Claims Data from the USA

Abiola Oladapo, Yanyu Wu, Mei Lu, Sepehr Farahbakhshian, Bruce Ewenstein

Blood (2019) 134 (Supplement_1): 4692.

https://doi.org/10.1182/blood-2019-122749

Published: 2019

Journal Articles

Prevalence and Burden of Major Bleeding Events in Patients with Von Willebrand Disease Based on Claims Data from the USA

Mei Lu, MD MSc, Abiola Oladapo, PhD MSc, BPharm, Yanyu Wu, BA, MS, PhD, Sepehr Farahbakhshian, BSc, MSc, Bruce Ewenstein, MD PhD

Blood (2018) 132 (Supplement 1): 2222.

https://doi.org/10.1182/blood-2018-99-113293

Published: 2018

Journal Articles

Estimating the Cost Savings and Cost Effectiveness of Low Dose Immune Tolerance Induction (ITI) Therapy with Bypassing Agent Prophylaxis Compared to High Dose ITI and Low Dose ITI

Gili Kenet, MD, Abiola Oladapo, PhD BPharm, Josh Epstein, PhD, Thompson Christin, PhD, Aaron Novack, Diane J. Nugent, MD

Blood (2017) 130 (Supplement 1): 4632.

https://doi.org/10.1182/blood.V130.Suppl_1.4632.4632

Published: 2017

NARROW

Early Anemia Response in Patients with Myelofibrosis Treated with Pacritinib in Real-Word Clinical Settings

Transplant Related Outcomes in Patients with Hemophagocytic Lymphohistiocytosis Treated with Emapalumab As a Bridge to Hematopoietic Stem Cell Transplantation: The Real-HLH Study

Real-Word Effectiveness of Pacritinib in Patients with Myelofibrosis Who Have Thrombocytopenia and Anemia

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (INTO-HLH) Patient Registry: Study Design and Clinical Characteristics

Real-World Treatment Patterns and Outcomes in Patients with Primary Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Interim Analysis Results

Hematologic Improvement Experienced By Pacritinib-Treated Patients with Myelofibrosis in Real-World Clinical Settings

Real-World Treatment Patterns and Outcomes Among Patients with Secondary Hemophagocytic Lymphohistiocytosis Treated with Emapalumab in the United States: The Real-HLH Study

Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Study Design

Real-World Treatment Patterns and Outcomes Among Patients with Primary Hemophagocytic Lymphohistiocytosis with and without Infection at Diagnosis and Treated with Emapalumab: The Real-HLH Study

Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study

Avatrombopag Treatment Response in Patients with Immune Thrombocytopenia: A Real-World Evidence Study

Real-World Demographic and Clinical Characteristics of Patients Initiating Avatrombopag in the US: The Real-AVA Study

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): The into-HLH Registry

Real-World Treatment Patterns and Outcomes in Patients with Hemophagocytic Lymphohistiocytosis (HLH) and Other Clinical Conditions Treated with Emapalumab: The Real-HLH Study Design

Retrospective Chart Review of Gastrointestinal Bleeding in Patients with Von Willebrand Disease

Prevalence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: A Retrospective US Claims Database Analysis

Analysis of Bleeding and Treatment Patterns in Children and Adolescents before and after Von Willebrand Disease Diagnosis Using Data from a US Medical Claims Database

Estimation of the Economic Burden Associated with Major Surgery Due to Von Willebrand Disease Based on Claims Data from the USA

Prevalence and Burden of Major Bleeding Events in Patients with Von Willebrand Disease Based on Claims Data from the USA

Estimating the Cost Savings and Cost Effectiveness of Low Dose Immune Tolerance Induction (ITI) Therapy with Bypassing Agent Prophylaxis Compared to High Dose ITI and Low Dose ITI

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only